Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Under the FDA’s new leadership, 2025 saw the approval of 46 new molecular entities and 10 new biologics, matching the pace of recent years. The agency’s review process remained on schedule, suggesting that the transition in senior management has not disrupted innovation pipelines. Analysts note that the steady approval volume underscores continued investment in drug development across small‑molecule and biologic platforms. The data signal that regulatory stability persists despite leadership changes.
ANS: I don’t take a dime from Pfizer or any other big pharma company. If and when you decide to visit a library instead of relying on conspiracy sites, you’ll find we develop low cost, patent free vaccines that bypass...
Researchers evaluated a school‑based albendazole deworming program among 3,200 children aged 5‑12 in Yunnan province. Baseline surveys showed a 42% helminth infection rate, which fell to 13% after a single annual dose. The intervention also correlated with modest gains in...
JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...
OpenAI unveiled ChatGPT for Healthcare, extending its popular conversational AI into hospitals and health systems. The offering follows the recent launch of a consumer‑focused health tool, signaling a broader push into clinical environments. OpenAI says the service will integrate with...
A panel of leading emergency physicians, intensivists, and radiologists released an expert consensus outlining a structured validation pathway for internal jugular vein ultrasound (IJU) tools. The framework delineates three validation phases—technical performance, operator reproducibility, and clinical outcome impact—backed by specific...
A recent systematic review examined acupuncture as a therapeutic option for cancer‑related fatigue, analyzing data from 18 randomized controlled trials involving over 2,000 patients. The analysis found that acupuncture produced modest but statistically significant reductions in fatigue severity compared with...
A multidisciplinary research team has unveiled a new analytical framework that fuses high‑resolution climate data with population health metrics to assess climate‑related health vulnerability. The platform leverages machine‑learning‑driven spatial modeling, incorporating temperature, air‑quality, and socioeconomic indicators to predict disease risk...
From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...
A new study links specific microbial communities to the integrity of tight junction proteins in the bovine gut, showing that a higher abundance of *Ruminococcus* and *Lactobacillus* correlates with stronger barrier function. Metagenomic sequencing and intestinal tissue analysis revealed a...
Researchers at the Chinese Academy of Sciences have engineered aluminum‑stabilized Pickering emulsions (ASPE) that act as deformable adjuvants, providing mechanical cues to dendritic cells. By adjusting nanoparticle crystallinity, the interfacial stiffness can be tuned to activate the mechanosensitive PIEZO1 channel,...
Researchers created the first patient‑derived iPSC model carrying the de novo L271H CACNA1D (Ca_v1.3) variant linked to neurodevelopmental disease. The study shows that Ca_v1.3 is the dominant L‑type calcium channel in neural progenitor cells, where the mutation drives heightened spontaneous calcium...
Researchers have demonstrated that genetic disruption of the inhibitory receptor TIGIT markedly amplifies the anti‑tumor activity of low‑avidity T cells. In mouse models, TIGIT‑deficient T cells infiltrated tumors more efficiently and induced significant tumor regression, especially when paired with existing...
Researchers have identified specific WRKY transcription factors that enhance disease resistance in Cucurbita moschata, commonly known as winter squash. Using genome‑wide association studies and CRISPR‑mediated knock‑outs, the team pinpointed WRKY45 and WRKY70 as key regulators against Phytophthora blight. Field trials...
Researchers have identified a noncanonical isoform of the TRPM4 ion channel that directly regulates intestinal fluid secretion and absorption. Using mouse models and human intestinal organoids, the study showed that loss of this isoform leads to dysregulated electrolyte transport and...
Researchers have discovered that loss of the RNA methyltransferase METTL3 accelerates glioma progression by reprogramming macrophage lipid metabolism. The study shows METTL3‑deficient tumor cells induce lipid accumulation in tumor‑associated macrophages, creating an immunosuppressive microenvironment that fuels tumor growth. Mechanistic analysis...
On January 9, 2026 Bioengineer.org published a suite of research highlights spanning nanomedicine, parasitology, medical imaging, climate‑health analytics, and plant genetics. The pieces report that chlorella‑based nanogels markedly suppress lung injury inflammation, albendazole effectively reduces helminth burdens in Yunnan children, and an...
Our man @mroliverbarnes $MRK $RVMD https://t.co/vUssAaRo5e US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of nearly $19bn, in what would be the latest big deal in the red-hot biotechnology...
#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx
Sanofi announced that the FDA rejected its experimental multiple‑sclerosis therapy, labeling the decision unexpected. The agency raised substantive questions late in the review process, leaving insufficient time for Sanofi to amend its submission. The setback threatens the anticipated launch of...
We're learning more about our immune system from a new, comprehensive, multi-omic atlas in @ScienceMagazine today, such as the stronger immune system in women and the age-related features of immunosenescence https://t.co/4B85BwohBb https://t.co/DHNIUKcQmE
Illumina announced the appointment of Eric Green, former director of the National Human Genome Research Institute and a pioneering geneticist, as its new chief medical officer. Green will lead the company’s clinical strategy, regulatory affairs, and diagnostic product development. The...
Researchers at the University of Notre Dame have demonstrated that leaf spectral reflectance measured from airborne or satellite sensors can predict the expression of key stress‑related genes. By sampling sugar maple and red maple leaves in Wisconsin and Michigan, they...
In the post-AlphaFold era, drug discovery is on a tear —Genome-wide virtual screening @ScienceMagazine https://t.co/GPyjSK6PcM —Transforming the industry in many ways @TheEconomist https://t.co/ppAMkbFqMp
Researchers at Sanford Burnham Prebys and Duke‑NUS have demonstrated that human embryonic stem cell‑derived cortical neurons can be grafted directly into the lesion cavity of mice after ischemic stroke, survive, mature into NeuN‑positive neurons, and re‑establish long‑range connections. By tracing...
Recent open‑access research confirms that women experience more severe Alzheimer’s pathology than men, with female 5xFAD mice developing larger, less compact amyloid‑β plaques. Transcriptomic analysis revealed that female microglia up‑regulate glycolytic metabolism, antigen‑presentation pathways, and a distinct type‑I interferon signature,...
Researchers have uncovered new molecular pathways that melanoma cells use to dodge immune surveillance, focusing on PD‑L1 up‑regulation and downstream signaling. A high‑throughput CRISPR‑Cas9 screen pinpointed several previously unknown evasion genes, enabling a targeted combination‑therapy approach. Early‑phase trials combining checkpoint...
Despite thousands of staff cuts, retirements, and leadership departures at the FDA in 2025, the agency’s drug reviewers largely maintained their review schedules. An internal analysis shows that median approval times for new molecular entities shifted by less than one...
Researchers at Texas A&M have shown that metallic “nanoflower” nanoparticles can protect and repair brain cells by improving mitochondrial health. In cell cultures, the nanoflowers sharply lowered reactive oxygen species and enhanced mitochondrial integrity within a day, and in C....
$LLY runs a psoriatic arthritis marketing study of Zepbound hoping to boost sales of Taltz. @elaineywchen sees right through it. Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms https://t.co/pcmEhIZgWY
Eli Lilly’s Phase 3b trial shows its weight‑loss blockbuster Zepbound (tirzepatide) can amplify the efficacy of an existing autoimmune therapy in a targeted patient cohort. The combination yielded superior clinical endpoints compared with the autoimmune drug alone, suggesting a synergistic...
Ryan's story notes that it's hard to tell exactly what killed Rampart. The faltering gene therapy field, specific scientific challenges, (any internal conflict). Maybe all of the above? No matter what, though, another sign of the cold wind blowing through...
Rampart Bioscience, a stealth biotech founded less than 15 months ago with a $125 million Series A, announced its closure after failing to advance its non‑viral gene‑therapy platform. The company had aimed to address delivery challenges that have limited viral vectors, but...
The plan to revolutionize cancer treatment by tracking and responding to evolution of tumor, emergence of resistance, and multimodal AI https://t.co/9PhOrtkiBM @Cancer_Cell @ARPA_H
Anti-aging and organ rejuvenation strategies, a review https://t.co/ZycCqjZwKk @CellStemCell Figure summary of cellular reprogramming efforts https://t.co/YKgGKukuYb
MoonLake Immunotherapeutics has re‑filed its FDA application for a novel therapy targeting a rare dermatological disorder, aiming to overcome earlier regulatory setbacks. The company highlighted new clinical data showing a 45% improvement in lesion clearance among trial participants. Simultaneously, three...
The science of regulatory T cells (Tregs) got the @NobelPrize last year. Now a first-rate review of where they are headed in the clinical arena https://t.co/4xjNAeG3MV https://t.co/MZCDyBc4jq
Rapid sterility testing (RST) is reshaping pharmaceutical quality control by cutting release times to roughly six days and providing objective, non‑visual detection methods. Nelson Labs highlights its ATP bioluminescence platform, which requires product‑specific validation, expanded organism panels, and interference studies...
The FDA’s 2025 drug and biologic approval tally fell sharply amid a year of internal upheaval. Approvals dropped about 15% compared with 2024, reflecting slower review times as thousands of staff departed and senior leadership changed. The agency’s operational instability...
Predictions for cell therapy and gene therapy in 2026. Most interesting is the "Prasad Paradox", meaning a general state of contradiction at the FDA biologics division around laxness and strictness, including misapplication of the concept of "bespoke" therapies.
The U.S. Department of Health and Human Services (HHS) failed to overturn a federal court order that barred the launch of its 340B rebate pilot. A three‑judge panel of the U.S. Court of Appeals affirmed the lower‑court injunction, keeping the...
Man, not my lucky day with cloning. A positive control plasmid had one of its lac operators and the -10 element of the T5 promoter removed during cloning. Gonna screen a few more. https://t.co/O09jf6Qf7F
Mathai on quarterly conference calls? Parabilis Medicines raises $305 million as CEO warms to an IPO By @ADeAngelis_bio https://t.co/h6I9BXDuLS via @statnews
A wave of workforce reductions swept the biotech sector in early 2024, with Tessera Therapeutics cutting 90 employees (about 35% of its staff) to prioritize its AATD and sickle‑cell programs after a $275 million Regeneron partnership. Similar cuts hit companies ranging...
Vanda Pharmaceuticals’ sleep‑aid Hetlioz was again rejected by the FDA for a jet‑lag indication, despite the agency acknowledging positive efficacy in trials. The regulator objected to Vanda’s reliance on phase‑advance protocols, deeming them insufficiently representative of real‑world travel conditions. The...
The article examines how governments are loosening regulations to accommodate the fast‑moving digital health sector, especially AI‑driven diagnostics and telemedicine. Recent policy proposals aim to streamline FDA approvals, expand data‑sharing frameworks, and create sandboxes for experimental AI tools. OpenAI’s latest...
Charles River Laboratories announced that CEO James C. Foster will retire on May 5 after more than a decade at the helm, and the board has named longtime COO Dr. Laura Miller as his successor. The transition comes as the company seeks...
Drug Hunter’s 2025 resource roundup highlights the ten most accessed tools that support daily drug‑discovery workflows. The suite includes practical PK calculators, bioisostere and covalent inhibitor cheat sheets, a searchable structure and patent database, and a series of 25 Flash...
This week's Biotech Scorecard newsletter: Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expected in February https://t.co/XTI2wySnbB
1/ Found the perfect ChIP-seq dataset on GEO. Then saw "hg19" in the methods. Now you need to remap everything to hg38 before you can integrate it with your data. And the authors didn't share their processing pipeline. https://t.co/3Ui4dyEnkb
